- Home
- PHAR
PHAR
Pharming Group N.V.
as of 02-25-2026 10:30am EST
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
| Founded: | 1988 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $38.00 | AVG Volume (30 days): | 33.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $7.50 - $21.34 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 27.75% | Revenue Growth (next year): | 9.39% |
| P/E Ratio: | 3041.22 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Compare PHAR vs Leading Stocks
See how PHAR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PHAR Pharming Group N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.